This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open AccessArticle
Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings
by
Ilaria Attili
Ilaria Attili
,
Carla Corvaja
Carla Corvaja ,
Gianluca Spitaleri
Gianluca Spitaleri
,
Pamela Trillo Aliaga
Pamela Trillo Aliaga
,
Ester Del Signore
Ester Del Signore ,
Antonio Passaro
Antonio Passaro *
and
Filippo de Marinis
Filippo de Marinis
Division of Thoracic Oncology, European Institute of Oncology, IRCCS, 20141 Milan, Italy
*
Author to whom correspondence should be addressed.
Submission received: 18 June 2024
/
Revised: 9 July 2024
/
Accepted: 17 July 2024
/
Published: 19 July 2024
Simple Summary
This study is a real-world study on a large cohort of patients with EGFR-mutant non-small-cell lung cancer (NSCLC) who progressed on osimertinib, focusing on access to subsequent treatments and progression patterns, including central nervous system (CNS) progression. Almost half of these patients had no access to further treatments due to worsening of clinical conditions or death. The outcomes of standard platinum-based chemotherapy were dismal and in line with those reported in the literature. Notably, intracranial disease progression was a rare event during osimertinib, whereas it occurred in half the patients during standard chemotherapy. Overall, the data highlight the clinical unmet needs in the treatment sequencing of single agent osimertinib and platinum-based chemotherapy alone, confirming the role of combination approaches and treatments in improving CNS control.
Abstract
Background: Platinum-based chemotherapy is the current standard treatment option in patients with EGFR-mutant non-small-cell lung cancer (NSCLC) who progress on osimertinib. However, outcomes with chemotherapy are dismal, and the treatment of central nervous system (CNS) disease is an unmet need in this setting. Methods: Patients with EGFR-mutant NSCLC who were candidates to receive osimertinib in the metastatic setting at our Center from 2015 to 2022 were retrospectively evaluated to identify patients who received standard platinum-based chemotherapy post-osimertinib. Data were collected on treatment outcomes, with a focus on brain metastases and progression patterns. Results: A total of 220 patients received indication for osimertinib in the study period; n = 176 had adequate follow-up data. Overall, n = 117 patients experienced disease progression on osimertinib. The median time to osimertinib progressive disease (PD) was 15 months (95% confidence interval CI 13–18). Of them, 51 patients (45%) had no access to further treatments. Of the remaining patients, n = 8 received experimental treatments, and n = 55 received standard platinum-based chemotherapy and were considered for this study. Median duration of chemotherapy was 3 months (95% CI 2–5); the best responses among 53 evaluable patients were observed as follows: 15% partial response/complete response (PR/CR), 40% stable disease (SD), 45% PD. Median progression-free survival (PFS) and overall survival (OS) were 3 (95% CI 2–5) and 10 (95% CI 6–15) months, respectively. All patients had baseline and follow-up brain radiologic assessments, and n = 23 had brain metastases at the start of chemotherapy. With a median follow-up of 13 months, intracranial PD occurred in 47% patients, being the first site of PD in 59% of cases. The median time for intracranial (IC) PD was 2 months (95% CI 2–7). IC PD occurred as oligometastatic in 29%, whereas in 71% of cases, it was associated with systemic PD. Conclusions: Access to subsequent treatments and CNS progression are confirmed unmet needs in EGFR-mutant NSCLC patients. Clinical and CNS-specific outcomes in patients receiving standard chemotherapy after the failure of osimertinib are dismal. Novel upfront treatment options with demonstrated prolonged PFS and better CNS outcomes may help address this important issue.
Share and Cite
MDPI and ACS Style
Attili, I.; Corvaja, C.; Spitaleri, G.; Trillo Aliaga, P.; Del Signore, E.; Passaro, A.; de Marinis, F.
Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings. Cancers 2024, 16, 2589.
https://doi.org/10.3390/cancers16142589
AMA Style
Attili I, Corvaja C, Spitaleri G, Trillo Aliaga P, Del Signore E, Passaro A, de Marinis F.
Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings. Cancers. 2024; 16(14):2589.
https://doi.org/10.3390/cancers16142589
Chicago/Turabian Style
Attili, Ilaria, Carla Corvaja, Gianluca Spitaleri, Pamela Trillo Aliaga, Ester Del Signore, Antonio Passaro, and Filippo de Marinis.
2024. "Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings" Cancers 16, no. 14: 2589.
https://doi.org/10.3390/cancers16142589
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details
here.
Article Metrics
Article Access Statistics
For more information on the journal statistics, click
here.
Multiple requests from the same IP address are counted as one view.